An interventional study of I-HTC in Dementia, sponsored by New York University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by New York University · Not applicable, Interventional, and Supportive care
This is an NIH Stage IB single-arm feasibility study will adapt and test the Inpatient Hospice Transitions Checklist (I-HTC), an Epic-embedded intervention supporting hospice eligibility assessment and clinician-surrogate communication for hospitalized persons living with dementia.
This NIH Stage IB study will develop, adapt, and pilot test the Inpatient Hospice Transitions Checklist (I-HTC), an Epic-embedded intervention supporting hospice eligibility assessment and clinician-surrogate communication for hospitalized persons living with dementia aged 60 years and older at NYU Langone Health. The intervention includes a hospice eligibility guide, a structured communication checklist, and a clinician frequently asked questions guide. Three sequential components include surveys with approximately 30 interdisciplinary acute care clinicians to refine intervention content; training and usability testing with approximately 10 clinicians and advance care planning experts to refine the Epic build and workflow integration; and a single-arm feasibility pilot involving approximately 40 clinicians and 100-110 patient-surrogate dyads.
Component 1 will assess clinician preferences, current hospice transition workflows, and communication needs.
Component 2 will assess usability through the System Usability Scale and structured walkthroughs.
Component 3 will evaluate feasibility through checklist use, clinician activation, and EHR documentation fidelity, with additional assessments of usability, workflow integration, hospice enrollment, surrogate understanding of hospice, satisfaction, and communication quality.
2,230 studies on the registry are indexed under Dementia; 549 are open to participants now.
This study's planned enrollment of 150 is above the median of 83 across 1,669 interventional studies indexed under Dementia.
Browse Dementia studies →New York University is the lead sponsor of 123 studies on the registry; 32 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinicians: Physicians, nurse practitioners, physician assistants, nurses, or social workers practicing in acute care; participate in goals-of-care, advance care planning (ACP), hospice, or care transition discussions for hospitalized adults with dementia; and can complete study activities in English; and use the electronic health record for clinical documentation and patience care (EPIC)
Surrogates: Adults aged =18 years identified as the legally authorized representative, healthcare proxy, or next of kin who participate in goals-of-care, ACP, or hospice-related discussions during hospitalization and can complete study communication in English.
PLWD Inclusion Criteria: Adults aged ≥60 years admitted to an acute care inpatient service who lack decisional capacity, have an EHR-documented dementia diagnosis, are identified through the NYU Dementia Epic Registry from the ED-LEAD trial and a "No" response to the Mandatory Surprise Question ("Would you be surprised if this person were to die within the next 6 months?"), and have clinical circumstances prompting goals-of-care or hospice-related discussions.
Exclusion Criteria:
Clinicians: Individuals who do not routinely participate in ACP, hospice, or care transition communication; decline or do not complete required training; or share responsibility for a patient encounter with an enrolled senior clinician.
Surrogates: Not the primary decision-maker for the PLWD and unable to find or contact the LAR for consent
Usual Care Arm: To be used by acute care clinicians with surrogates of eligible hospitalized persons living with dementia
Behavioral: I-HTC
The I-HTC intervention will include 1) hospice eligibility guide, 2) the I-HTC checklist for hospice communication, and 3) a frequently asked questions (FAQ) guide for clinicians.
Feasibility of the I-HTC Checklist EHR Intervention (Reported by Clinicians)
Frequency and proportion of I-HTC use during eligible encounters, clinician activation (accessing the I-HTC at least once), fidelity of ACP and hospice-related EHR documentation, and integration into clinical workflows.
Time frame: Within 1 month of trial completion
Usability of the I-HTC Intervention as Reported by Clinicians
Usability: Clinician-reported ease of use and usability of the I-HTC, assessed using the System Usability Scale.
Time frame: Within 1 month of intervention delivery to surrogate
Hospice enrollment of the PLWD
Proportion of participating PLWD who enroll in hospice, determined through EHR review.
Time frame: Within 1 month of intervention receipt (PLWD-EHR data)
Surrogate understanding of hospice care
Brief questionnaire focused on surrogate-reported understanding of hospice services and their role in supporting the person living with dementia.
Time frame: within 1 month of intervention receipt (surrogate)
Surrogate satisfaction
Satisfaction with care, assessed using the FAMCARE scale.
Time frame: within 1 month of intervention receipt (surrogate)
Quality of communication as reported by the surrogate after receiving the I-HTC intervention
Quality of communication: Surrogate-reported quality of clinician-surrogate communication, assessed using the Quality of Communication questionnaire.
Time frame: within 1 month of intervention receipt (surrogate)
Plan to share: No — De-identified participant data will be shared with the ASCENT consortium but clinician data is not able to be shared.
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.